Martin Shkreli launched 'unmonitored' trial in Cyprus for Retrophin drug without FDA oversight

Shkreli's "insistence on taking shortcuts" in order to get a PKAN drug to market "drastically delayed the development of the drug," prosecutors said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.